Fibroblast Growth Factor 23 as a Potential Target for Treatment

Abstract

This fibroblast growth factor-23 (FGF-23) has been found as a circulating hormone and pathogenic factor in many disease
conditions. This review focuses on recent advances in FGF-23 as a therapeutic target, including fibroblast growth factor receptors
(FGFR) tyrosine kinase inhibitor, FGF-23 antibody, FGF-23 C-terminal peptide, CYP24A1 inhibitor, and FGF-23 antagonist. We
also update the advantages and disadvantages of targeting upstream and downstream molecules in FGF-23 signaling pathways.